ZNF304 and colorectal carcinoma: To test whether this tissue-specific methylation could be a noninvasive marker, we developed and applied targeted bisulfite sequencing analysis (3 CpG sites in the LIFR and ZNF304 genes were selected) in the cfDNA pilot cohort with 9 cfDNA samples from CRC patients and 5 cfDNA samples from healthy controls.